实体瘤的分子遗传学：将研究转化为临床实践。我们目前能做的：乳腺癌。
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
作者信息
Lakhani S R
机构信息
The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Mary-Jean Mitchell Green Building, Chester Beatty Laboratories, Fulham Road, London SW3 6JB, UK.
出版信息
Mol Pathol. 2001 Oct;54(5):281-4. doi: 10.1136/mp.54.5.281.
Abstract
Breast cancer is a common solid malignancy in women. Over the past decade, much progress has been made in understanding the biology of breast cancer. The use of molecular and immunohistochemical techniques is providing insights that will allow us to tailor the management of patients with breast cancer. In this review, progress in the understanding of lobular carcinoma in situ and atypical ductal hyperplasia, the use of the molecular marker CerbB2, and information gained from the morphological analysis of tumours arising in patients with BRCA1 and BRCA2 mutations is discussed.
摘要
乳腺癌是女性常见的实体恶性肿瘤。在过去十年中，我们对乳腺癌生物学的理解取得了很大进展。分子和免疫组化技术的应用为我们提供了深刻见解，使我们能够针对乳腺癌患者制定个性化治疗方案。在这篇综述中，我们将讨论在原位小叶癌和非典型导管增生的认识方面取得的进展、分子标志物CerbB2的应用，以及从对携带BRCA1和BRCA2突变患者所患肿瘤的形态学分析中获得的信息。
相似文献
1
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.实体瘤的分子遗传学：将研究转化为临床实践。我们目前能做的：乳腺癌。
Mol Pathol. 2001 Oct;54(5):281-4. doi: 10.1136/mp.54.5.281.
2
3
Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology.
Histopathology. 1999 Sep;35(3):195-200. doi: 10.1046/j.1365-2559.1999.00815.x.
4
[Classification of preinvasive breast and carcinoma in situ: doubts, controversies, and proposal for new categorizations].[乳腺原位癌及癌前病变的分类：疑问、争议与新分类建议]
Bull Cancer. 2004 Dec 1;91 Suppl 4:S205-10.
5
BRCA-associated breast cancer: absence of a characteristic immunophenotype.BRCA相关乳腺癌：缺乏特征性免疫表型。
Cancer Res. 1998 May 1;58(9):1839-42.
6
Lobular neoplasia.小叶瘤变
Surg Oncol Clin N Am. 2014 Jul;23(3):487-503. doi: 10.1016/j.soc.2014.03.002. Epub 2014 Apr 16.
7
miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.BRCA1和BRCA2种系突变携带者的正常乳腺组织及浸润性乳腺癌中的miRNA表达模式。
Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.
8
Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.家族性乳腺癌的表型分析：BRCAx肿瘤与BRCA1、BRCA2携带者及非家族性乳腺癌的比较
Eur J Surg Oncol. 2015 May;41(5):641-6. doi: 10.1016/j.ejso.2015.01.021. Epub 2015 Feb 17.
9
Molecular and biologic markers of premalignant lesions of human breast.人类乳腺癌前病变的分子和生物学标志物
Adv Anat Pathol. 2002 May;9(3):185-97. doi: 10.1097/00125480-200205000-00002.
10
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.遗传性乳腺癌患者乳腺实质的病理特征，包括BRCA1和BRCA2突变携带者。
Cancer. 2003 Jan 1;97(1):1-11. doi: 10.1002/cncr.11048.
引用本文的文献
1
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.男性携带BRCA1和BRCA2基因突变者患前列腺癌后，其表型更具侵袭性。
Br J Cancer. 2008 Jan 29;98(2):502-7. doi: 10.1038/sj.bjc.6604132. Epub 2008 Jan 8.
2
Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer.间变性淋巴瘤激酶在人类乳腺癌的不同亚型中表达。
Biochem Biophys Res Commun. 2007 Jun 29;358(2):399-403. doi: 10.1016/j.bbrc.2007.04.137. Epub 2007 Apr 30.
3
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.13号染色体上特定于BRCA1相关卵巢癌和输卵管癌的假定肿瘤抑制基因的分子证据。
Mol Pathol. 2002 Oct;55(5):305-9. doi: 10.1136/mp.55.5.305.
4
Methods of molecular analysis: assessing losses and gains in tumours.分子分析方法：评估肿瘤中的缺失和增益
Mol Pathol. 2002 Feb;55(1):25-8. doi: 10.1136/mp.55.1.25.
本文引用的文献
1
Lobular carcinoma in situ: A rare form of mammary cancer.小叶原位癌：一种罕见的乳腺癌形式。
Am J Pathol. 1941 Jul;17(4):491-496.3. doi: 10.3322/canjclin.32.4.234.
2
Loss of heterozygosity in lobular carcinoma in situ of the breast.乳腺小叶原位癌中的杂合性缺失
Clin Mol Pathol. 1995 Apr;48(2):M74-8. doi: 10.1136/mp.48.2.m74.
3
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology.乳腺导管内增生性病变诊断与分类不一致的原因。欧盟乳腺筛查病理学工作组
Eur J Cancer. 2000 Sep;36(14):1769-72. doi: 10.1016/s0959-8049(00)00181-7.
4
Molecular portraits of human breast tumours.人类乳腺肿瘤的分子图谱
Nature. 2000 Aug 17;406(6797):747-52. doi: 10.1038/35021093.
5
The transition from hyperplasia to invasive carcinoma of the breast.乳腺从增生到浸润性癌的转变。
J Pathol. 1999 Feb;187(3):272-8. doi: 10.1002/(SICI)1096-9896(199902)187:3<272::AID-PATH265>3.0.CO;2-2.
6
Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology.来自12个国家的23名欧洲病理学家在诊断乳腺疾病和报告癌的预后特征方面取得的一致性。欧盟乳腺筛查病理学工作组。
Virchows Arch. 1999 Jan;434(1):3-10. doi: 10.1007/s004280050297.
7
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.使用重组人源化抗p185HER2/neu单克隆抗体联合顺铂对化疗难治性HER2/neu过表达转移性乳腺癌患者进行受体增强化学敏感性的II期研究。
J Clin Oncol. 1998 Aug;16(8):2659-71. doi: 10.1200/JCO.1998.16.8.2659.
8
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.散发性乳腺癌与涉及BRCA1和BRCA2基因突变的癌症之间差异的多因素分析。
J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45. doi: 10.1093/jnci/90.15.1138.
9
Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations.携带BRCA1和BRCA2突变的乳腺癌患者对放射治疗的反应及预后
Radiother Oncol. 1998 May;47(2):129-36. doi: 10.1016/s0167-8140(98)00023-1.
10
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.携带BRCA1基因种系突变的乳腺癌患者的生存情况和肿瘤特征
Lancet. 1998 Jan 31;351(9099):316-21. doi: 10.1016/s0140-6736(97)07065-7.
Zotero 插件